OncLive TV

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.

Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).

Vaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Rohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.

Vikas Kumar Singh, MD, discusses findings from the phase 3 GETUG-AFU V05 VESPER (NCT01812369) and JAVELIN Bladder 100 (NCT02603432) trials in patients with bladder cancer.

Praful K. Ravi, MB, BChir, MRCP, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer.

Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.

François-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.

Atish D. Choudhury, MD, PhD, discusses key biomarkers that may assist in the prediction of PARP inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC).

June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.

Michael J. Fallon, MD, discusses supportive care considerations for patients with relapsed/refractory multiple myeloma.

Eunice Wang, MD, discusses ongoing clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm.

Aditya Bardia, MD, MPH, discusses the significance of the FDA approval of sacituzumab govitecan in patients with pretreated hormone receptor–positive, HER2-negative metastatic breast cancer and key data from the phase 3 TROPiCS-02 trial.

Rohit Kumar, MD, discusses the current and future uses of triplet combinations in metastatic renal cell carcinoma.

Carmelo Carlo-Stella, MD, PhD, discusses the evaluation of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Bartosz Chmielowski, MD, discusses the current treatment landscape of metastatic melanoma.

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.

John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.

David Siegel, MD, PhD, discusses the importance of investigating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.

Henry S. Park, MD, MPH, discusses key considerations when selecting an optimal treatment approach for patients with stage II and III non–small cell lung cancer.

Petros Grivas, MD, PhD, discusses the investigation of enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma.

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer. 

Joseph D. Khoury, MD, discusses the importance of differentiating between blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.